FDA Greenlights Light-Activated Gel for Basal Cell Carcinoma
The FDA approved aminolevulinic acid hydrochloride 10% (Ameluz) combined with photodynamic therapy for adults with superficial basal cell carcinoma. In a phase III trial, 66% of treated patients achieved complete response versus 5% with vehicle. The non-surgical option is intended for use with a specific red-light lamp.
The approval extends an existing treatment platform, as the same gel-and-lamp combination already carried FDA clearance for actinic keratoses on the face and scalp. The phase III trial enrolled 187 adults with histologically confirmed disease, and the primary endpoint required both clinical and histological confirmation of clearance—a rigorous standard for evaluating treatment response.
Superficial basal cell carcinoma accounts for roughly 15% to 20% of the more than 3.5 million annual U.S. cases. These lesions frequently appear on the trunk and extremities, sometimes as multiple growths. While surgery remains the standard approach, this new option addresses patients with numerous lesions or those in cosmetically sensitive areas where excision may be undesirable.
This approval could meaningfully expand treatment choices for a very common cancer, particularly for patients with multiple lesions or tumors in visible areas where surgery carries cosmetic concerns. The in-office, non-surgical nature may reduce recovery burden and procedure-related anxiety, though access depends on clinics having the specialized lamp and trained staff. Broader adoption may also influence future guideline updates and insurance coverage decisions, potentially reshaping standard practice for low-risk skin cancers over time.